Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company based in Brisbane, California, is focused on developing innovative targeted and immune-mediated therapies to combat cancer. Recently, the Compensation Committee of the Company’s Board of Directors awarded one employee nonqualified stock options to purchase 14,000 shares of its common stock under the Company’s 2023 Inducement Plan. These stock options will vest gradually over a four-year period, with 25% of the options vesting on the first anniversary of the employee’s start date, and the remaining shares vesting monthly thereafter, contingent on continued employment.
Tempest Therapeutics is dedicated to advancing a diverse portfolio of small molecule product candidates with tumor-targeted and immune-mediated mechanisms that show promise in treating various types of tumors. The company’s programs span from early research to later-stage investigation, including a randomized global study in first-line cancer patients. For more information about Tempest Therapeutics, visit the company’s website at www.tempesttx.com.
For inquiries from investors and media, please contact Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors. Tempest Therapeutics is committed to developing groundbreaking therapies for cancer treatment, pending approval by the FDA.